Biognosys, a next-generation proteomics biotech, has made the NULISA proteomics assay range commercially available.
The assay assortment is able to discover biomarkers in plasma and other biofluids, and was originally developed by Alamar Biosciences.
Following the two company’s strategic partnership that commenced earlier this year, Biognosys will be the provider of choice for the NULISA multiplex assay services.
Biognosys will now offer Alamar’s NULISAseq CNS Disease 120 and Inflammation 250 panels, which are run on the ARGO HT System.
The NULISA range, according to the company, enable the analysis of previously hard-to-measure chemokines, cytokines and markers of neurodegeneration.
The service requires 10μL of plasma, which allow the maximisation of information capture from small clinical samples.
Christopher Bunker, VP Biopharma Business Development for Alamar Biosciences, commented: “The increasing demand to discover novel markers of therapeutic response requires both a comprehensive survey of the proteome and the precise measurement of specific proteins to differentiate clinical outcomes."
"We are thrilled to partner with Biognosys to provide biopharma researchers with a complete suite of proteomic solutions for biomarker studies.”
